Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: Keith Feral who wrote (73)	5/15/2007 9:15:13 AM
From: Keith Feral	Read Replies (2) \| Respond to of 418

AMGN is in big trouble today. Cofactor eliminaes the market for leucovorin and epogen. No anemia or neutropeniam in Cofactor trials. I think the improvements in chemo delivery will eliminate the need for post chemo drugs like epogen to treat the side effects. Cofactor increases the response rate at the same time it eliminates the side effects. AMGN should have done a little better job of DD when they went out and paid $2 billion for ABGX. ANX is looking like the disruptive technology to improve the standard of care for all chemo.